KLARIA PHARMA Aktie

 

Due to the change of auditor in Klaria Holding AB, the board has decided to move the date of the annual general meeting to 26 May 2026 at 10:00 and the publication of the 2025 annual report to 5 May 2026. The reason for the change of auditor from BDO Sweden to Azets Revision och Rådgivning AB was to avoid a conflict of interest with the business development assignment that BDO LLP's UK Life Sciences M&A is performing together with Klaria. To give Azets the opportunity to carry out the audit without excessive time pressure, the board has decided to change the date of the 2025 annual...

Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting (all in accordance with the proposal presented in the notice convening the extra general meeting, which have been made available on the Company's website www.klaria.com). · In light of the Company's collaboration with BDO LLP's UK Life Sciences M&A team regarding business development efforts in strategically important markets, the extraordinary general meeting unanimously resolved that the...

Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting (all in accordance with the proposal presented in the notice convening the extra general meeting, which have been made available on the Company's website www.klaria.com). · In light of the Company's collaboration with BDO LLP's UK Life Sciences M&A team regarding business development efforts in strategically important markets, the extraordinary general meeting unanimously resolved that the...

The shareholders of Klaria Pharma Holding AB (publ), org.nr 556959–2917, are hereby summoned to extraordinary general meeting on March 19, 2026, at 10.00 a.m. CET, at Advokatfirman Glimstedts Stockholm office, Sturegatan 46 in Stockholm. Right to participate and notice of participation Shareholders who wish to participate in the extra general meeting must: · be entered in the share register maintained by Euroclear Sweden AB on March 11, 2026, and · notify the company of their participation no later than March 13, 2026, by mail to Klaria Pharma Holding AB, Virdings Allé 2, 754 50...

Klaria Pharma Holding AB Annual Report 2024 The year in brief - Net sales amounted to 2.2 MSEK (8.5 MSEK) - Other operating income amounted to 0.1 MSEK (0.5 MSEK) - R&D costs amounted to 22.1 MSEK (25.0 MSEK) - Profit/loss after tax amounted to -47.8 MSEK (-35.8 MSEK) - Earnings per share amounted to -0.38 SEK (-0.36 SEK) - Cash flow from operations amounted to -11.9 MSEK (-9.1 MSEK) - Shareholder's equity as of December 31, 2024 amounted to 3.3 MSEK (41.1 MSEK) - Cash and cash equivalents as of December 31, 2024 amounted to 0.6 MSEK (1.2 MSEK)...